Taiwan Stock Exchange · Healthcare
SCI Pharmtech stock from India: price, numbers and tax
SCI Pharmtech (4119) is not currently available to trade on Paasa; this guide covers the price, the numbers and the Indian tax treatment.
By Paasa · Updated
SCI Pharmtech at a glance
- Price
- NT$55.50+NT$0.00 (0.00%)
- Market cap
- NT$6.63B
- Day range
- NT$55.10 – NT$55.90
- P/E
- 108.82
- Dividend yield
- 1.35%
- Volume
- 49.62K
- 1 month
- +0.18%
- 6 months
- +9.04%
- YTD
- +13.96%
- 1 year
- -7.50%
- 5 years
- -20.42%
SCI Pharmtech statements, FY2021–FY2025
| Fiscal year | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Revenue | NT$1.3B | NT$1.5B | NT$1.2B | NT$899.7M | NT$864.2M |
| Gross profit | NT$319.5M | NT$410.7M | NT$350.3M | NT$291.2M | NT$208.1M |
| Operating income | NT$155.2M | NT$198.3M | NT$160.3M | NT$404.3M | NT$63.3M |
| Net income | NT$107.4M | NT$534.7M | NT$294.7M | NT$308.8M | NT$55.7M |
| Earnings per share | NT$0.90 | NT$4.47 | NT$2.70 | NT$2.83 | NT$0.51 |
| EBITDA | NT$408.2M | NT$909.9M | NT$515.8M | NT$492.1M | NT$142.8M |
| Total assets | NT$6.9B | NT$7.2B | NT$6.7B | NT$5.0B | NT$4.2B |
| Total debt | NT$987.2M | NT$990.4M | NT$1.0B | NT$545.4M | NT$2.2M |
| Cash and short-term investments | NT$74.8M | NT$692.8M | NT$1.0B | NT$264.4M | NT$692.6M |
| Shareholders' equity | NT$5.4B | NT$5.5B | NT$5.1B | NT$3.6B | NT$3.3B |
| Operating cash flow | NT$220.3M | NT$860.5M | NT$215.8M | NT$296.6M | NT$280.3M |
| Free cash flow | −NT$389.7M | −NT$86.1M | −NT$813.6M | −NT$871.0M | −NT$494.7M |
| Capital expenditure | −NT$610.0M | −NT$946.6M | −NT$1.0B | −NT$1.2B | −NT$775.0M |
Fiscal years as reported, the latest ending 31 Dec 2025. Figures in TWD; a dash means the provider reported nothing for that line.
Peer comparison
| Company | Ticker | Price | Market cap |
|---|---|---|---|
| Sinphar Pharmaceutical | 1734.TW | NT$31.95 | NT$6.44B |
| Orient Pharma | 4166.TWO | $24.65 | $5.99B |
| Formosa Laboratories | 4746.TW | NT$48.80 | NT$5.87B |
| Hi-Clearance | 1788.TWO | $128.00 | $5.70B |
| OBI Pharma | 4174.TWO | $43.10 | $5.67B |
| Pacific Hospital Supply | 4126.TWO | $78.10 | $5.67B |
| Formosa Optical Technology | 5312.TWO | $89.50 | $5.38B |
| St.Shine Optical | 1565.TWO | $96.50 | $4.87B |
Peers as grouped by the data provider. This is not an investment recommendation.
Why invest in SCI Pharmtech from India
What SCI Pharmtech does
SCI Pharmtech, Inc., founded in 1987 and based in Taoyuan City, Taiwan, specializes in the comprehensive lifecycle of pharmaceutical components. The company's core operations involve the research and development, manufacturing, and global distribution of active pharmaceutical ingredients (APIs), chemical intermediates, and specialty chemicals. SCI Pharmtech operates in the Drug Manufacturers - Specialty & Generic industry within the Healthcare sector.
Paasa handles the paperwork
Investing abroad brings paperwork with it: remittance filings, capital gains reporting, foreign asset disclosure. Paasa prepares all of it for you. Your India-ready tax reports arrive at year end, ready to file.
Frequently asked questions
What tax do I pay in India when I sell SCI Pharmtech shares?
In India, gains on shares held for more than 24 months are long-term and taxed at 12.5%, and gains on shares held for 24 months or less are short-term and taxed at your income-tax slab rate. Both are worked out in rupees at the TWD/INR rate on the day you bought and the day you sold, so the currency move is part of the gain.